Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus grid laser versus laser alone for persistent diabetic macular oedema
ACTRN12611000063910Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Novartis. Primary endpoint: Improvement in vision. Started Apr 2010; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12611000063910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000063910.